David Hägg

Publications
Public outreach and news

Articles

Article: BMC MEDICINE. 2024;22(1):84

Estrogen-modulating treatment among mid-life women and COVID-19 morbidity and mortality: a multiregister nationwide matched cohort study in Sweden.

Elenis E; Kallner HK; Karalexi MA; Hägg D; Linder M; Fall K; Papadopoulos FC; Skalkidou A
Article: BMJ OPEN. 2023;13(2):e066057

Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study.

Reilev M; Jensen PB; Ranch LS; Egeberg A; Furu K; Gembert K; Hagg D; Haug U; Karlstad Ø; Reutfors J; Schäfer W; Schwartz S; Smits E; Holthius E; Herings R; Trifirò G; Kirchmayer U; Rosa AC; Belleudi V; Gini R; Støvring H; Hallas J
Article: NEUROLOGY AND THERAPY. 2022;11(4):1659-1676

Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study.

Forns J; Dudukina E; Hägg D; Szentkúti P; Gembert K; Plana E; Gilsenan A; Horváth-Puhó E; Ehrenstein V; Reutfors J; Rebordosa C
Article: INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. 2022;26(3):251-258

Health care utilisation in treatment-resistant depression: a Swedish population-based cohort study.

Brenner P; Nygren A; Hägg D; Tiger M; O'Hara M; Brandt L; Reutfors J
Article: JAAD INTERNATIONAL. 2021;3:63-75

Societal impact for patients with psoriasis: A nationwide Swedish register study.

Häbel H; Wettermark B; Hägg D; Villacorta R; Wennerström ECM; Linder M
Article: CLINICAL EPIDEMIOLOGY. 2020;12:737-744

The Occurrence of Metabolic Risk Factors Stratified by Psoriasis Severity: A Swedish Population-Based Matched Cohort Study.

Hajiebrahimi M; Song C; Hägg D; Andersson TM-L; Villacorta R; Linder M
Article: PLOS ONE. 2020;15(7):e0236434

A register-based approach to identifying treatment-resistant depression-Comparison with clinical definitions.

Hägg D; Brenner P; Reutfors J; Li G; DiBernardo A; Bodén R; Brandt L
Article: JOURNAL OF AFFECTIVE DISORDERS. 2019;249:242-252

Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators.

Forns J; Pottegård A; Reinders T; Poblador-Plou B; Morros R; Brandt L; Cainzos-Achirica M; Hellfritzsch M; Schink T; Prados-Torres A; Giner-Soriano M; Hägg D; Hallas J; Cortés J; Jacquot E; Deltour N; Perez-Gutthann S; Pladevall M; Reutfors J
Article: CNS DRUGS. 2019;33(4):383-395

Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources.

Pladevall-Vila M; Pottegård A; Schink T; Reutfors J; Morros R; Poblador-Plou B; Timmer A; Forns J; Hellfritzsch M; Reinders T; Hägg D; Giner-Soriano M; Prados-Torres A; Cainzos-Achirica M; Hallas J; Brandt L; Cortés J; Aguado J; Perlemuter G; Falissard B; Castellsagué J; Jacquot E; Deltour N; Perez-Gutthann S
Article: JOURNAL OF AFFECTIVE DISORDERS. 2018;238:674-679

Mortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden.

Reutfors J; Andersson TM-L; Brenner P; Brandt L; DiBernardo A; Li G; Hägg D; Wingård L; Bodén R
Article: CLINICAL EPIDEMIOLOGY. 2018;10:705-715

Young patients with risk factors prevalent in the elderly - differences in comorbidity depending on severity of psoriasis: a nationwide cross-sectional study in Swedish health registers.

Hajiebrahimi M; Linder M; Hägg D; Berglind IA; McElligott S; Valgardsson VS; Villacorta R; Sundström A
Article: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2017;18(4):583-590

Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.

Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
Article: BMC MEDICAL GENETICS. 2015;16:79

Hair shaft structures in EDAR induced ectodermal dysplasia.

Stecksén-Blicks C; Falk Kieri C; Hägg D; Schmitt-Egenolf M
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2015;29(3):452-456

Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).

Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
Article: PLOS ONE. 2013;8(5):e63619

The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.

Hägg D; Eriksson M; Sundström A; Schmitt-Egenolf M

All other publications

Conference publication: EUROPEAN PSYCHIATRY. 2022;65:S111

Association with severe and treatment-resistant depression among patients with inflammatory joint disease. Nationwide nested case-control study in Swedish registers.

Brenner P; Askling J; Stang P; Brandt L; Hagg D; Reutfors J
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2022;31:487-488

Brodalumab assessment of hazards: A multinational safety (brahms) study of a biological anti-psoriatic drug across six European countries

Reilev M; Jensen P; Stovring H; Ranch LS; Gini R; Bartolini CC; Trifiro G; Kirchmayer U; Rosa AC; Belleudi V; Haug U; Schwarz S; Schaefer W; Herings R; Smits E; Overbeek J; Holthuis E; Furu K; Gembert K; Hagg D; Tari M; Ientile V; Ingrasciotta Y; Egeberg A; Hallas J
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021;53:S77

Health care utilization in treatment-resistant depression: a Swedish population based cohort study

Brenner P; Nygren A; Hagg D; Tiger M; O'Hara M; Brandt L; Reutfors J
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:84-85

Occurrence of metabolic risk factors stratified by psoriasis severity: A Swedish population-based matched cohort study

Hagg D; Linder M; Hajiebrahimi M; Song C; Andersson TM-L; Villacorta R
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29:S589-S590

Agomelatine and other antidepressants and the risk of acute liver injury (ALI), a post authorisation safety study (PASS) in four European countries

Pladelvall M; Pottegard A; Schink T; Reutfors J; Morros R; Poblador-Plou B; Timmer A; Forns J; Hellfritzsch M; Reinders T; Hagg D; Giner-Soriano M; Prados-Torres A; Cainzos-Achirica M; Hallas J; Kollhorst B; Brandt L; Cortes J; Aguado J; Perlemuter G; Falissard B; Castellsague J; Jacquot E; Deltour N; Perez-Gutthann S
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2019;28:274-275

Antidepressant use in Denmark, Germany, Spain, and Sweden from 2009 to 2014: Incidence and comorbidities of antidepressant initiators

Forns J; Pottegard A; Reinders T; Poblador-Plou B; Morros R; Brandt L; Cainzos-Achirica M; Hellfritzsch M; Schink T; Prados-Torres A; Giner-Soriano M; Hagg D; Hallas J; Cortes J; Jacquot E; Deltour N; Perez-Gutthann S; Pladevall M; Reutfors J
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2019;28:104-105

Eye color and risk of ocular melanoma in patients with glaucoma - a Swedish register study combining data from the Swedish police Authority's register on passport applications and National Health Registers

Hagg D; Berglind IA; Kieler H; Linder M; Odsbu I
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2018;27:152

Treatment resistant depression as a risk factor for substance use disorders-A national register-based cohort study

Brenner P; Hagg D; DiBernardo A; Li G; Boden R; Brandt L; Reutfors J

Articles

All other publications

News from KI

Events from KI